Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt
Joint Authors
Bernardes, Miguel
C. Romão, Vasco
Santos, Maria José
Polido-Pereira, Joaquim
Duarte, Cátia
Nero, Patrícia
Miguel, Cláudia
Costa, José António
Pimentel-Santos, Fernando M.
Barcelos, Filipe
Costa, Lúcia
Melo Gomes, José António
Pereira da Silva, José Alberto
Branco, Jaime Cunha
Canas da Silva, José
Pereira da Silva, José António
Canhão, Helena
Fonseca, Joao Eurico
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-13, 13 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-04-27
Country of Publication
Egypt
No. of Pages
13
Main Subjects
Abstract EN
Objectives.
To compare the effectiveness of TNF inhibitors (TNFi) and tocilizumab in rheumatoid arthritis (RA) treatment, according to different response criteria.
Methods.
We included RA patients registered in the Rheumatic Diseases Portuguese Register treated with TNFi or tocilizumab for at least 6 months, between January 2008 and July 2013.
We assessed remission/low disease activity (LDA) at 6 months according to DAS28, CDAI, and SDAI, as well as Boolean ACR/EULAR remission and EULAR response rate, adjusting for measured confounders.
Results.
Tocilizumab-treated patients ( n = 95 ) presented higher baseline disease activity and were less frequently naïve to biologics compared to TNFi users ( n = 429 ).
Multivariate logistic regression analysis including the propensity score for receiving tocilizumab showed that patients treated with tocilizumab were more likely to achieve remission or LDA according to DAS28 (OR = 11.0/6.2, 95% CI 5.6–21.6/3.2–12.0), CDAI (OR = 2.8/2.6, 95% CI 1.2–6.5/1.3–5.5), or SDAI (OR = 3.6/2.5, 95% CI 1.5–8.7/1.1–5.5), as well as a good EULAR response (OR = 6.4, 95% CI 3.4–12.0).
However, both groups did not differ in Boolean remission (OR = 1.9, 95% CI 0.8–4.8) or good/moderate EULAR response (OR = 1.8, 95% CI 0.8–4.5).
Conclusions.
Compared with TNFi, tocilizumab was associated with greater likelihood of achieving DAS28, CDAI, and SDAI remission/LDA and EULAR good response.
Boolean remission and EULAR good/moderate response did not differ significantly between groups.
American Psychological Association (APA)
C. Romão, Vasco& Santos, Maria José& Polido-Pereira, Joaquim& Duarte, Cátia& Nero, Patrícia& Miguel, Cláudia…[et al.]. 2015. Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. BioMed Research International،Vol. 2015, no. 2015, pp.1-13.
https://search.emarefa.net/detail/BIM-1054857
Modern Language Association (MLA)
C. Romão, Vasco…[et al.]. Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. BioMed Research International No. 2015 (2015), pp.1-13.
https://search.emarefa.net/detail/BIM-1054857
American Medical Association (AMA)
C. Romão, Vasco& Santos, Maria José& Polido-Pereira, Joaquim& Duarte, Cátia& Nero, Patrícia& Miguel, Cláudia…[et al.]. Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-13.
https://search.emarefa.net/detail/BIM-1054857
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1054857